2025
Understanding the occurrence and determinants of catastrophic costs of rifampicin resistant tuberculosis in South Africa to inform a patient-centered care program
Wang Z, Ndebele F, Sibeko Z, Bohlela S, Segwaba P, Fanampe B, Setlhare L, Charalambous S, Van Rie A, Van Rie A. Understanding the occurrence and determinants of catastrophic costs of rifampicin resistant tuberculosis in South Africa to inform a patient-centered care program. International Journal Of Infectious Diseases 2025, 152: 107756. DOI: 10.1016/j.ijid.2024.107756.Peer-Reviewed Original ResearchPatient-centered approachAnnual household incomeCatastrophic costsFree State ProvinceHousehold incomeTB diagnosisIndirect cost dataRR-TB treatmentTB treatment episodesRandomized controlled trialsCare programTelephone interviewsSocial protection interventionsTrial participantsClinic visitsPatient costsMultiple imputationVulnerable populationsBackground TuberculosisIndirect costsControlled trialsFree of chargeEconomic burdenEconomic evaluationSouth AfricaEnvironMental Health: A Framework for an Emerging Field at the Intersection of the Environment and Mental Health Crises
Ratjen L, Goddard E, Gilcher E, Nguyen B, Kelley M, Feldman H, Akalaonu K, Nyhan K, Backhaus A, Lascurain M, Wyrtzen N, Smith S, Prabhu M, Lowe S, Chen K, Zimmerman J, Anastas P. EnvironMental Health: A Framework for an Emerging Field at the Intersection of the Environment and Mental Health Crises. GeoHealth 2025, 9: e2024gh001254. PMID: 39958831, PMCID: PMC11826329, DOI: 10.1029/2024gh001254.Peer-Reviewed Original ResearchCognitive healthReview of reviewsMental health conditionsMental health crisisAttention-deficit/hyperactivity disorderBehavioral healthMental healthHealth conditionsHealthPublic healthEconomic burdenWell-beingNeuropsychological healthHealth crisisSocial factorsContextual needsAttention-deficit/hyperactivityEnvironmental factorsGreen spacesHealthcareDementiaFunding strategiesConceptual frameworkFundingBurdenTraining Guidelines and Competencies for Serious Mental Illness (SMI) Psychology
Jansen M, Manning M, Gonzales L, DeLuca J, Stacy M. Training Guidelines and Competencies for Serious Mental Illness (SMI) Psychology. Psychological Services 2025, 22: 4-19. PMID: 38780553, DOI: 10.1037/ser0000854.Peer-Reviewed Original ResearchSerious mental illnessMental illnessTraining guidelinesMental health disciplinesMental health providersPostdoctoral training programsEvidence-based assessmentPsychological specialtiesTraining programEvidence-based practicePsychologyPsychologistsEvidence-based trainingHealth disciplinesHealth providersIllnessComprehensive trainingU.S. populationEconomic burdenTrainingGuidelinesPostdoctoralCliniciansProgramHigh-quality
2024
The Financial Burden of Localized and Metastatic Bladder Cancer
Scilipoti P, Moschini M, Li R, Lerner S, Black P, Necchi A, Rouprêt M, Shariat S, Gupta S, Morgans A, Psutka S, Kamat A. The Financial Burden of Localized and Metastatic Bladder Cancer. European Urology 2024 PMID: 39730299, DOI: 10.1016/j.eururo.2024.12.002.Peer-Reviewed Original ResearchMetastatic bladder cancerFinancial toxicityBacillus Calmette-GuerinBladder cancerRadical cystectomyFinancial burdenImpact of bladder cancerNon-muscle-invasive BCaSystematic reviewHigh-risk NMIBC patientsMuscle-invasive BCaNMIBCBurden of bladder cancerEconomic burdenHealth care systemImprove oncologic outcomesTreatment-related toxicityPreferred Reporting ItemsHigher financial burdenBladder cancer managementCases of complicationsRisk of FTBladder cancer treatmentImprove patient qualityPatient perspectiveEstimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study
Keogh-Brown M, Sumner T, Sweeney S, Vassall A, Jensen H. Estimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study. PLOS Medicine 2024, 21: e1004491. PMID: 39666614, PMCID: PMC11637336, DOI: 10.1371/journal.pmed.1004491.Peer-Reviewed Original ResearchConceptsGross domestic productMacroeconomic burdenCumulative gross domestic productReturn to investmentHigh-income householdsLow-income householdsDomestic productEconomic growthReduction targetsIndian economyEconomic gainsInvestmentEconomic impactEconomyCountriesHouseholdsBurden of TBEconomic burdenDisease burdenFundingImpact of TBLarge healthCase detectionTB-related deathsProvisionIntensive, Real-Time Data Collection of Psychological and Physiological Stress During a 96-Hour Field Training Exercise at a Senior Military College: Feasibility and Acceptability Cohort Study
Pojednic R, Welch A, Thornton M, Garvey M, Grogan T, Roberts W, Ash G. Intensive, Real-Time Data Collection of Psychological and Physiological Stress During a 96-Hour Field Training Exercise at a Senior Military College: Feasibility and Acceptability Cohort Study. JMIR Formative Research 2024, 8: e60925. PMID: 39422988, PMCID: PMC11530722, DOI: 10.2196/60925.Peer-Reviewed Original ResearchConceptsField training exercisePhysical fitnessArmy Reserve Officers' Training Corps cadetsDiagnosis of mental health disordersTraining exercisesPsychological resiliencePoor physical fitnessReserve Officer Training Corps cadetsSelf-reported injuriesMental health disordersField-based trainingData collectionDaily wear timeMilitary field training exercisePhysical readinessTesting adherenceParticipant acceptabilityWear timeHealth disordersMilitary readinessAcceptability surveyOccupational stressorsCohort studyProspective pilot studyEconomic burdenReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalHeart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Failure Reviews 2024, 29: 631-662. PMID: 38411769, PMCID: PMC11035416, DOI: 10.1007/s10741-024-10385-y.Peer-Reviewed Original ResearchRandomized controlled trialsHeart failureUnmet medical needAssociated with considerable morbidityDisease burdenPatient outcomesSymptomatic HF patientsEconomic burdenOverview of heart failureComposite cardiovascular deathClinical practice guidelinesGlobal healthcare concernMedical needPoor patient outcomesTargeted literature reviewPreventable disease burdenTreatment landscapeHFmrEF/HFpEFHF hospitalizationHF patientsCardiovascular deathElectronic databasesPatient characteristicsStudy characteristicsMortality riskMIF contribution to progressive brain diseases
Matejuk A, Benedek G, Bucala R, Matejuk S, Offner H, Vandenbark A. MIF contribution to progressive brain diseases. Journal Of Neuroinflammation 2024, 21: 8. PMID: 38178143, PMCID: PMC10765708, DOI: 10.1186/s12974-023-02993-6.Peer-Reviewed Original ResearchConceptsBrain diseasesMultiple sclerosisAlzheimer's diseaseMacrophage migration inhibitory factorModulation of neuroinflammationNumerous neurologic diseasesMigration inhibitory factorProgressive brain diseaseNew therapeutic strategiesInflammatory mediatorsChronic inflammationAutoimmune diseasesVascular diseaseNervous system developmentNeurologic diseaseNeuroendocrine functionPsychiatric disordersTherapeutic strategiesEconomic burdenNeurological diseasesNew biomarkersInhibitory factorNeurodegenerative pathologiesDiseaseNovel therapeutics
2023
Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.
Armengol V, Darras B, Abulaban A, Alshehri A, Barisic N, Ben-Omran T, Bernert G, Castiglioni C, Chien Y, Farrar M, Kandawasvika G, Khadilkar S, Mah J, Marini-Bettolo C, Osredkar D, Pfeffer G, Piazzon F, Pitarch Castellano I, Quijano-Roy S, Saito K, Shin J, Vázquez-Costa J, Walter M, Wanigasinghe J, Xiong H, Griggs R, Roy B. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability. Neurology Clinical Practice 2023, 14: e200224. PMID: 38107546, PMCID: PMC10723640, DOI: 10.1212/cpj.0000000000200224.Peer-Reviewed Original ResearchSurveyed health care providersProvider survey responsesHealth care providersSpinal muscular atrophyEconomic burdenNewborn screeningBarriers to treatmentMitigate such inequalitiesCare providersClinical careQualitative studyTreated patientsOutcome measuresMotor strengthGenetic testingSpinal muscular atrophy type 1Muscular atrophyProvidersSurvey responsesTreatment of spinal muscular atrophyLife-saving treatmentMuscle weaknessProgressive muscle weaknessNormal lifeTreatment costsHealthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims. Blood 2023, 142: 2348. DOI: 10.1182/blood-2023-181909.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationHealthcare resource utilizationAcute myeloid leukemia patientsRetrospective cohort studyIndex dateMyeloid leukemia patientsAML patientsAML diagnosisR patientsDiagnosis codesEconomic burdenPPPM costsCohort studyContinuous enrollmentND patientsLeukemia patientsMedical costsLarge US administrative claims databaseRefractory acute myeloid leukemia patientsHigher healthcare resource utilizationUS administrative claims databaseMore outpatient encountersNon-HSCT patientsNon-transplant recipientsOlder AML patientsHeart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments.
Sen S. Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments. The American Journal Of Managed Care 2023, 29: s180-s186. PMID: 37677742, DOI: 10.37765/ajmc.2023.89415.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyReduced ejection fractionHeart failureEjection fractionEconomic burdenManagement of HFrEFPresence of comorbiditiesEmergency department visitsVentricular ejection fractionDisease-modifying therapiesPoor treatment adherenceHealth care systemDepartment visitsMedical therapyPatient factorsComorbid conditionsMedication costsTreatment adherenceOptimal treatmentOutpatient carePreventable hospitalizationsIndividual patientsHigh riskTarget dosesMedical costsGlobal, regional, and country-level cost of leptospirosis due to loss of productivity in humans
Agampodi S, Gunarathna S, Lee J, Excler J. Global, regional, and country-level cost of leptospirosis due to loss of productivity in humans. PLOS Neglected Tropical Diseases 2023, 17: e0011291. PMID: 37616329, PMCID: PMC10482283, DOI: 10.1371/journal.pntd.0011291.Peer-Reviewed Original ResearchConceptsGross domestic productDisability-adjusted life yearsProductivity costsWorld Bank data repositoryLoss of productivityHealth expenditure dataEconomic burden estimatesHigher productivity costsDomestic productExpenditure dataInternational dollarsOverall economic burdenMonetary valueEconomic burdenAsia-Pacific regionIntangible costsLife yearsEconomic costsCost estimatesIncome countriesDiseases of povertyPartial estimatesCostProductivityCountriesSurface Electrical Impedance Myography Detects Skeletal Muscle Atrophy in Aged Wildtype Zebrafish and Aged gpr27 Knockout Zebrafish
Rutkove S, Chen Z, Pandeya S, Callegari S, Mourey T, Nagy J, Nath A. Surface Electrical Impedance Myography Detects Skeletal Muscle Atrophy in Aged Wildtype Zebrafish and Aged gpr27 Knockout Zebrafish. Biomedicines 2023, 11: 1938. PMID: 37509577, PMCID: PMC10377526, DOI: 10.3390/biomedicines11071938.Peer-Reviewed Original ResearchMuscle atrophySkeletal muscle healthG protein-coupled receptorsField of sarcopeniaAssociated with riskSkeletal muscle massAll-cause mortalityDetect muscle atrophyWorld's population agesOlder adultsSkeletal muscle atrophyAtrophy of skeletal muscleHealthcare systemMuscle healthOrphan G protein-coupled receptorAge-related conditionsElectrical impedance myographyMuscle massSarcopeniaAging StudyEconomic burdenPopulation agingKO animalsCardiovascular diseaseMyofiber atrophyOut-of-pocket costs and catastrophic healthcare expenditure for families of children requiring surgery in sub-Saharan Africa
Yap A, Olatunji B, Negash S, Mweru D, Kisembo S, Masumbuko F, Ameh E, Lebbie A, Bvulani B, Hansen E, Philipo G, Carroll M, Hsu P, Bryce E, Cheung M, Fedatto M, Laverde R, Ozgediz D. Out-of-pocket costs and catastrophic healthcare expenditure for families of children requiring surgery in sub-Saharan Africa. Surgery 2023, 174: 567-573. PMID: 37385869, DOI: 10.1016/j.surg.2023.05.010.Peer-Reviewed Original ResearchConceptsCatastrophic healthcare expenditureFamilies of childrenHealthcare expendituresChildren's surgeryPocket costsPediatric surgical patientsMultivariate logistic regressionPediatric operating roomIntensive resource utilizationPocket healthcare costsUniversal healthcare coverageChart reviewSurgical patientsSubgroup analysisClinical dataAfrican hospitalsHealthcare costsEconomic burdenMedian annual incomeSurgeryOlder ageLogistic regressionHealthcare coverageOperating roomOlder childrenEPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing Cholangitis
Levy C, Bowlus C, Kachru N, Ammirabile G, Walker S, Alleman C, Kowdley K. EPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing Cholangitis. Value In Health 2023, 26: s184. DOI: 10.1016/j.jval.2023.03.992.Peer-Reviewed Original ResearchEE191 An Investigation of the Economic Burden of Treatment for Namd/Dme on Treatment Recipients and Caregivers in the US
Tabano D, Watane A, Gale R, Cox O, Garmo V, Hill S, Longworth L, Oluboyede Y, Ahmed A, Patel N. EE191 An Investigation of the Economic Burden of Treatment for Namd/Dme on Treatment Recipients and Caregivers in the US. Value In Health 2023, 26: s94. DOI: 10.1016/j.jval.2023.03.492.Peer-Reviewed Original ResearchDysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat N, Mani A. Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients 2023, 15: 2323. PMID: 37242206, PMCID: PMC10222271, DOI: 10.3390/nu15102323.Peer-Reviewed Original ResearchConceptsFatty liver diseaseLiver diseaseHepatocellular carcinomaAlcoholic fatty liver diseaseNonalcoholic fatty liver diseaseInsulin-resistant liverDiet-induced steatosisCurrent therapeutic effortsDysregulation of lipidAccumulation of lipidsHepatic fatPrevalent conditionSevere stagesGenetic predispositionGlucose metabolismHealthcare costsEconomic burdenTherapeutic effortsDiseaseNAFLDCanonical insulinSteatosisLiverCirrhosisSteatohepatitisFrequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States
Naidu S, Sutton M, Gao W, Fine J, Xie J, Desai N, Owens A. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal Of Medical Economics 2023, 26: 682-690. PMID: 37170479, DOI: 10.1080/13696998.2023.2208966.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyDefinitive diagnosisHypertrophic cardiomyopathyHCM diagnosisMedicare Supplemental databasesIBM MarketScan CommercialEmergency room visitsAdministrative claims dataMisclassification of patientsEligible patientsMarketScan CommercialMost patientsRoom visitsAlternative diagnosesPotential misdiagnosesCardiovascular conditionsInappropriate treatmentDatabase studyClaims dataHealthcare costsDiagnostic journeyPatientsEconomic burdenCurrent studyDiagnostic historyImpact of Hospital Readmissions Reduction Program Policy on 30-Day and 90-Day Readmissions in Patients With Acute Myocardial Infarction: A 10-Year Trend From the National Readmissions Database
Sana M, Kumi D, Park D, Asemota I, DeAngelo S, Yilmaz M, Hammo H, Shaka H, Vij A. Impact of Hospital Readmissions Reduction Program Policy on 30-Day and 90-Day Readmissions in Patients With Acute Myocardial Infarction: A 10-Year Trend From the National Readmissions Database. Current Problems In Cardiology 2023, 48: 101696. PMID: 36921652, DOI: 10.1016/j.cpcardiol.2023.101696.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramAcute myocardial infarction hospitalizationsCenters for Medicare & Medicaid ServicesAcute myocardial infarctionSecondary analysisHealth care utilizationReadmissions Reduction ProgramCare utilizationNational Readmission DatabaseImpact of Hospital Readmissions Reduction ProgramMyocardial infarctionMedicare hospitalizationsLength of stayMedicaid ServicesAll-causeHospital readmissionReadmissions DatabaseReduction programsEconomic burdenPrimary analysisReadmissionHospitalDownward trend
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply